KRAS mutations in combination with primary tumor size are not associated with a worse prognosis in early Non-Small Cell Lung Cancer

Purpose: The aim of this study it to investigate the combined impact of KRAS mutational status and tumor size on overall survival and risk of death in stage I and II NSCLC. Methods: All consecutive patients molecularly assessed and diagnosed between 2016-2018 with stage I-II NSCLC in the region of West Sweden were included in this multi-center retrospective study. Primary study outcome was overall survival (OS) and risk of death (HR). Results: Out of 310 Stage I-II NSCLC patients, 37% harbored an activating mutation in the KRAS gene (KRASMUT). Our study confirmed staging and tumor size as prognostic factors. KRAS mutational status was not found to impact overall survival and no difference in risk of death was observed when combining KRAS mutational status and primary tumor size. Conclusions: KRAS mutations in combination with primary tumor size are not associated with a worse prognosis in stage I and II NSCLC.

[1]  L. Akyürek,et al.  KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer , 2022, Cancers.

[2]  L. Fournel,et al.  Updated Prognostic Factors in Localized NSCLC , 2022, Cancers.

[3]  Yantian Lv,et al.  Prognostic factors of survival in patients with non-small cell lung cancer: a competing risk model using the SEER database , 2021, Translational cancer research.

[4]  Myung Ah Lee,et al.  Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. , 2021, The Lancet. Oncology.

[5]  M. Schuler,et al.  HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2. , 2021, European journal of cancer.

[6]  M. Mathieu,et al.  KRAS G12C fragment screening renders new binding pockets , 2021, Small GTPases.

[7]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[8]  A. Addeo,et al.  KRAS G12C Mutations in NSCLC: From Target to Resistance , 2021, Cancers.

[9]  L. Voltolini,et al.  Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[10]  A. Cortellini,et al.  Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors , 2021, Pharmaceutics.

[11]  S. Rothschild,et al.  Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations , 2021, Cancers.

[12]  T. Burns,et al.  Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Wankhede.  Evaluation of Eighth AJCC TNM Sage for Lung Cancer NSCLC: A Meta-analysis , 2020, Annals of Surgical Oncology.

[14]  W. John,et al.  KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. , 2020, Cancer treatment and research communications.

[15]  F. Detterbeck,et al.  The eighth edition TNM stage classification for lung cancer: What does it mean on main street? , 2018, The Journal of thoracic and cardiovascular surgery.

[16]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[17]  David R. Jones,et al.  KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma , 2016, The American journal of surgical pathology.

[18]  C. Lovly,et al.  Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆. , 2016, Lung cancer.

[19]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  F. Shepherd,et al.  KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy , 2015, Oncotarget.

[21]  C. Langer,et al.  Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy , 2015, Oncotarget.

[22]  A. Iafrate,et al.  The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  P. Snijders,et al.  KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  D. Gerber,et al.  Baseline tumour measurements predict survival in advanced non-small cell lung cancer , 2013, British Journal of Cancer.

[25]  Jie Yang,et al.  Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. , 2013, Lung cancer.

[26]  E. Holmberg,et al.  Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy , 2012, Lung cancer international.

[27]  John V Heymach,et al.  Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.

[28]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[29]  M. Okada,et al.  Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. , 2005, The Journal of thoracic and cardiovascular surgery.

[30]  L. V. van't Veer,et al.  Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.